This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): CC-4047, Actimid, pomalidomide, Imnovid (EU)
Actimid is a member of a new class of novel immunomodulatory drugs, or IMiDs, which are chemically similar to thalidomide. Like thalidomide, actimid affects the immune system in multiple ways including the inhibition of angiogenesis and inflammatory cytokine production.
Another major target may be the ligase protein, cereblon (CRBN; http://www.nature.com/leu/journal/v26/n11/full/leu2012119a.html).
Additional information available to subscribers only: